Ustekinumab Improves Psoriasis without Altering T Cell Cytokine Production, Differentiation, and T Cell Receptor Repertoire Diversity

Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years

(2012) A.B. Kimball et al.   BRITISH JOURNAL OF DERMATOLOGY

Calcineurin Inhibitors Suppress Cytokine Production from Memory T Cells and Differentiation of Naïve T Cells into Cytokine-Producing Mature T Cells

(2012) Kenshiro Tsuda et al.   PLoS One

Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: Long-term results from a phase 2/3 clinical trial

(2011) Atsuyuki IGARASHI et al.   JOURNAL OF DERMATOLOGY

Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): Results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials

(2011) Mark Lebwohl et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): Results from analyses of infections and malignancy from pooled phase II and III clinical trials

(2011) Kenneth B. Gordon et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Restoration of peripheral blood T cell repertoire complexity during remission in advanced cutaneous T cell lymphoma

(2010) Kei-ichi Yamanaka et al.   ARCHIVES OF DERMATOLOGICAL RESEARCH

Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis

(2010) Christopher E.M. Griffiths et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-term efficacy of biologics in the treatment of psoriasis: what do we really know?

(2009) Eihab A. Alwawi et al.   Dermatologic Therapy

Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis

(2009) Vinod Chandran et al.   JOURNAL OF AUTOIMMUNITY

Safety of Etanercept in Patients at High Risk for Mycobacterial Tuberculosis Infections

(2009) R. AGGARWAL et al.   JOURNAL OF RHEUMATOLOGY

Psoriasis

(2009) Frank O. Nestle et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-term data in the treatment of psoriasis

(2008) D. Thaçi   BRITISH JOURNAL OF DERMATOLOGY

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

(2008) Craig L Leonardi et al.   LANCET

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

(2008) Kim A Papp et al.   LANCET

The differentiation of human TH-17 cells requires transforming growth factor-β and induction of the nuclear receptor RORγt

(2008) Nicolas Manel et al.   NATURE IMMUNOLOGY

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

(2007) Alan Menter et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY